The effect of an antibiotic stewardship program on tigecycline use in a Tertiary Care Hospital, an intervention study.
Antibiotic stewardship
FDA-approved indication
Lebanon
Off-label use
Tigecycline
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
06 Aug 2020
06 Aug 2020
Historique:
received:
04
03
2020
accepted:
30
07
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
29
1
2021
Statut:
epublish
Résumé
A drug-oriented antibiotic stewardship intervention targeting tigecycline utilization was launched at Makassed General Hospital, Beirut, Lebanon, in 2016 as a part of a comprehensive Antibiotic Stewardship Program (ASP). In this study, we evaluated the effect of this intervention on changing tigecycline prescription behavior in different types of infections, patient outcome and mortality, along with tigecycline drug use density, when compared to an earlier period before the initiation of ASP. This is a retrospective chart review of all adult inpatients who received tigecycline for more than 72 h between Jan-2012 and Dec-2013 [period (P) 1 before ASP] and between Oct-2016 and Dec-2018 [period (P) 2 during ASP]. Tigecycline was administered to 153 patients during P1 and 116 patients during P2. The proportion of patients suffering from cancer, those requiring mechanical ventilation, and those with hemodynamic failure was significantly reduced between P1 and P2. The proportion of patients who received tigecycline for FDA-approved indications increased from 19% during P1 to 78% during P2 (P < 0.001). On the other hand, its use in off-label indications was restricted, including ventilator-associated pneumonia (26.1% in P1, 3.4% in P2, P < 0.001), hospital-acquired pneumonia (19.6% in P1, 5.2% in P2, P = 0.001), sepsis (9.2% in P1, 3% in P2, P = 0.028), and febrile neutropenia (15.7% in P1, 0.9% in P2, P < 0.001). The clinical success rate of tigecycline therapy showed an overall significant increase from 48.4% during P1 to 65.5% during P2 (P = 0.005) in the entire patient population. All-cause mortality in the tigecycline-treated patients decreased from 45.1% during P1 to 20.7% during P2 (P < 0.0001). In general, mean tigecycline consumption decreased by 55% between P1 and P2 (P < 0.0001). The drug-oriented ASP intervention targeting tigecycline prescriptions improved its use and patient outcomes, where it helped curb the over-optimistic use of this drug in off-label indications where it is not a suitable treatment option.
Sections du résumé
BACKGROUND
BACKGROUND
A drug-oriented antibiotic stewardship intervention targeting tigecycline utilization was launched at Makassed General Hospital, Beirut, Lebanon, in 2016 as a part of a comprehensive Antibiotic Stewardship Program (ASP). In this study, we evaluated the effect of this intervention on changing tigecycline prescription behavior in different types of infections, patient outcome and mortality, along with tigecycline drug use density, when compared to an earlier period before the initiation of ASP.
METHODS
METHODS
This is a retrospective chart review of all adult inpatients who received tigecycline for more than 72 h between Jan-2012 and Dec-2013 [period (P) 1 before ASP] and between Oct-2016 and Dec-2018 [period (P) 2 during ASP].
RESULTS
RESULTS
Tigecycline was administered to 153 patients during P1 and 116 patients during P2. The proportion of patients suffering from cancer, those requiring mechanical ventilation, and those with hemodynamic failure was significantly reduced between P1 and P2. The proportion of patients who received tigecycline for FDA-approved indications increased from 19% during P1 to 78% during P2 (P < 0.001). On the other hand, its use in off-label indications was restricted, including ventilator-associated pneumonia (26.1% in P1, 3.4% in P2, P < 0.001), hospital-acquired pneumonia (19.6% in P1, 5.2% in P2, P = 0.001), sepsis (9.2% in P1, 3% in P2, P = 0.028), and febrile neutropenia (15.7% in P1, 0.9% in P2, P < 0.001). The clinical success rate of tigecycline therapy showed an overall significant increase from 48.4% during P1 to 65.5% during P2 (P = 0.005) in the entire patient population. All-cause mortality in the tigecycline-treated patients decreased from 45.1% during P1 to 20.7% during P2 (P < 0.0001). In general, mean tigecycline consumption decreased by 55% between P1 and P2 (P < 0.0001).
CONCLUSION
CONCLUSIONS
The drug-oriented ASP intervention targeting tigecycline prescriptions improved its use and patient outcomes, where it helped curb the over-optimistic use of this drug in off-label indications where it is not a suitable treatment option.
Identifiants
pubmed: 32762758
doi: 10.1186/s12941-020-00377-9
pii: 10.1186/s12941-020-00377-9
pmc: PMC7412806
doi:
Substances chimiques
Anti-Bacterial Agents
0
Tigecycline
70JE2N95KR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
BMC Infect Dis. 2010 Sep 29;10:287
pubmed: 20920273
Lancet Infect Dis. 2018 Dec;18(12):e379-e394
pubmed: 30292478
Antimicrob Agents Chemother. 2008 Nov;52(11):4115-20
pubmed: 18725447
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855067
Clin Microbiol Infect. 2005 Oct;11 Suppl 5:4-16
pubmed: 16138814
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii15-24
pubmed: 23772042
Surg Infect (Larchmt). 2017 Jan;18(1):1-76
pubmed: 28085573
J Microbiol Immunol Infect. 2011 Feb;44(1):45-51
pubmed: 21531352
J Chemother. 2020 May 2;:1-17
pubmed: 32364030
BMC Infect Dis. 2019 Mar 29;19(1):293
pubmed: 30925909
Infection. 2015 Feb;43(1):37-43
pubmed: 25367409
Infection. 2017 Aug;45(4):459-467
pubmed: 28265870
World J Emerg Surg. 2017 Jul 10;12:29
pubmed: 28702076
J Glob Antimicrob Resist. 2019 Dec;19:83-84
pubmed: 31493527
Am J Infect Control. 1988 Jun;16(3):128-40
pubmed: 2841893
Microb Drug Resist. 2018 Mar;24(2):166-174
pubmed: 28650688
Front Microbiol. 2017 Mar 27;8:497
pubmed: 28396656
Diagn Microbiol Infect Dis. 2015 Oct;83(2):183-6
pubmed: 26164275
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Intensive Care Med. 2018 Jun;44(6):925-928
pubmed: 29675566
Microb Drug Resist. 2017 Sep;23(6):733-743
pubmed: 28080212
Infect Dis Clin North Am. 2014 Jun;28(2):195-214
pubmed: 24857388
Medicine (Baltimore). 2016 Mar;95(11):e3126
pubmed: 26986165
Clin Infect Dis. 2010 Jan 15;50(2):133-64
pubmed: 20034345
New Microbiol. 2015 Apr;38(2):121-36
pubmed: 25915055
J Hosp Infect. 2016 Jan;92(1):47-53
pubmed: 26616413
J Microbiol Immunol Infect. 2015 Oct;48(5):540-4
pubmed: 24685280
J Infect Public Health. 2019 Mar - Apr;12(2):195-199
pubmed: 30385238
Diagn Microbiol Infect Dis. 2010 Nov;68(3):307-11
pubmed: 20955916
ACS Sens. 2018 Nov 26;3(11):2202-2217
pubmed: 30350967
Intensive Care Med. 2014 Jul;40(7):988-97
pubmed: 24871500
Int J Infect Dis. 2013 Aug;17(8):e638-43
pubmed: 23523562
J Infect. 2010 May;60(5):401-2
pubmed: 20211200
PLoS One. 2013 May 30;8(5):e65621
pubmed: 23738018
Int J Infect Dis. 2015 Jul;36:56-61
pubmed: 26004171
Int J Antimicrob Agents. 2013 Jun;41(6):527-35
pubmed: 23590898
Int J Infect Dis. 2014 Dec;29:139-44
pubmed: 25449248
Clin Infect Dis. 2014 Jul 15;59(2):e10-52
pubmed: 24973422
Antimicrob Resist Infect Control. 2019 Feb 20;8:41
pubmed: 30828445